| 2026-08-21 16:34 |
8-K |
["3.01"] |
other |
0.05
|
Nasdaq delisting notice due to stock price below $1.00; no M&A activity indicated. |
SEC · detail |
| 2026-08-12 16:27 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine 8-K filing of Q2 2026 earnings results; no M&A signals detected. |
SEC · detail |
| 2026-06-18 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.25
|
Shareholder letter on business strategy and BD opportunities; insufficient detail to assess M&A signal. |
SEC · detail |
| 2026-06-12 08:00 |
8-K |
["3.01"] |
other |
0.05
|
BioCardia reports Nasdaq delisting compliance status via ATM equity offering; no M&A signals. |
SEC · detail |
| 2026-06-08 08:00 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
BioCardia announced an at-the-market equity offering of 3.5M shares; no M&A implications. |
SEC · detail |
| 2026-06-05 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
FDA meeting minutes on CardiAMP therapy; routine regulatory disclosure unrelated to M&A. |
SEC · detail |
| 2026-05-28 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Regulatory update on CardiAMP cell therapy from Japan's PMDA; no M&A signal present. |
SEC · detail |
| 2026-05-21 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Clinical trial results announcement; no M&A signals present. |
SEC · detail |
| 2026-05-15 08:05 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement for Q1 2026; no M&A-related signals present. |
SEC · detail |
| 2026-05-08 08:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
FDA pre-submission meeting outcome on medical device approval pathway; no M&A signal. |
SEC · detail |
| 2026-04-28 08:00 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
Patent allowance announcement for Heart3D imaging software; no M&A indicators present. |
SEC · detail |